|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ChiCTR |
|
Last refreshed on:
|
18 April 2017 |
|
Main ID: |
ChiCTR-RPC-16010078 |
|
Date of registration:
|
2016-12-04 |
|
Prospective Registration:
|
Yes |
|
Primary sponsor: |
|
|
Public title:
|
The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib
|
|
Scientific title:
|
The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib |
|
Date of first enrolment:
|
2016-12-13 |
|
Target sample size:
|
imatinib group:150;dasatinib group:150;nilotinib group:150; |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://www.chictr.org.cn/showproj.aspx?proj=17145 |
|
Study type:
|
Relative factors research |
|
Study design:
|
Case series
|
|
Phase:
|
Post-market
|
|
|
Countries of recruitment
|
|
China
| | | | | | | |
|
Contacts
|
|
Name:
|
Zeng Jing
|
|
Address:
|
139 Middle Renmin Road, Changsha, Hunan, China
|
|
Telephone:
|
+86 15200925731 |
|
Email:
|
zj693664673@163.com |
|
Affiliation:
|
The Second Xiangya Hospital of Central South University |
|
|
Name:
|
Xu Ping
|
|
Address:
|
139 Middle Renmin Road, Changsha, Hunan, China
|
|
Telephone:
|
+86 13874882504 |
|
Email:
|
xuping1109@163.com |
|
Affiliation:
|
The Second Xiangya Hospital of Central South University |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Patients diagnosed with chronic myelogenous leukemia and taking imatinib, dasatinib or nilotinib regularly are included.
Exclusion criteria: Patients allergic to imatinib, dasatinib or nilotinib; Patients stopping taking imatinib, dasatinib or nilotinib for any reasons are excluded.
Age minimum:
Age maximum:
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
chronic myelogenous leukemia
|
|
Intervention(s)
|
|
imatinib group:The determination of concentration and genotypes;dasatinib group:The determination of concentration and genotypes;nilotinib group:The determination of concentration and genotypes;
|
|
Primary Outcome(s)
|
|
plasma concentrations of imatinib, dasatinib or nilotinib;genotype;
|
|
Source(s) of Monetary Support
|
|
raise (funds/etc.) independently
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|